Scantox Group Acquires Gentronix Ltd

Discovery Life Sciences Acquires Gentest Business from Corning Incorporated

April 5, 2022

Biotechnology

Discovery Life Sciences has acquired the Gentest business unit from Corning Incorporated to expand its in vitro ADME and toxicology reagent and services offering. The deal complements Discovery’s recent acquisition of In Vitro ADMET Laboratories (IVAL) and strengthens its hepatocyte, microsome and ADME-related product and contracted research capabilities for pharmaceutical and life sciences customers.

Labcorp Acquires Toxikon Corporation

November 18, 2021

Healthcare Services

Labcorp has acquired Toxikon Corporation, a Bedford, Massachusetts-based contract research organization that provides nonclinical in vivo and in vitro testing for pharmaceutical, biotech and medical device clients. The acquisition expands Labcorp Drug Development's nonclinical testing capabilities and creates a strategic Boston-area footprint; Toxikon reported approximately $40 million in annual revenue and the deal closed in December 2021.

Charles River Laboratories Acquires Retrogenix

March 31, 2021

Biotechnology

Charles River Laboratories has acquired Retrogenix Limited, a UK-based contract research organization specializing in cell microarray technology for target receptor identification and off-target profiling. The transaction was for approximately £35 million in cash with up to an additional £5 million contingent on performance, and Retrogenix becomes part of Charles River's Discovery and Safety Assessment segment to expand large-molecule and cell therapy discovery capabilities.

3E Acquires Toxnot

December 12, 2022

Cloud & SaaS

3E, a global provider of EHS&S and product compliance solutions, acquired Toxnot, a SaaS platform for product compliance and supply chain sustainability. The acquisition expands 3E's supply chain transparency and sustainability capabilities by integrating Toxnot's digital product passport and supplier data-sharing technology into its compliance suite.

QIAGEN Acquires Genoox

May 12, 2025

Biotechnology

QIAGEN has signed a definitive agreement to acquire Genoox, the developer of the AI-powered Franklin clinical genomics platform, for $70 million in cash plus up to $10 million in milestone payments. The acquisition adds Genoox's cloud-based AI interpretation capabilities to QIAGEN Digital Insights, expanding QIAGEN's clinical genomics and diagnostic software offerings for labs and healthcare organizations worldwide.

Malvern Panalytical Acquires Creoptix AG

January 11, 2022

Medical Devices

Malvern Panalytical has acquired Creoptix AG, a Swiss specialist in next-generation bioanalytical sensors and the WAVEsystem instrumentation, to strengthen its drug discovery and biopharma capabilities. The acquisition integrates Creoptix's Grating-Coupled Interferometry (GCI) technology into Malvern Panalytical's portfolio to expand molecular interaction analysis offerings for pharmaceutical and life-sciences customers.